Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Bleb Vascularity Clinical Trial

Official title: Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Status Active, not recruiting

Clinical Trial Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bleb Vascularity
• Conjunctival Scarring

• NCT number: NCT00815594
• Study type: Interventional
• Source: Capital Medical University
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: December 2008
• Completion date: May 2009